BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15015668)

  • 1. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
    Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
    J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
    Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
    Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
    Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
    World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
    Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
    Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
    Shibahara I; Miyasaka K; Sekiguchi A; Ishiyama H; Inukai M; Yasui Y; Watanabe T; Sato S; Hide T; Kumabe T
    J Clin Neurosci; 2021 Apr; 86():202-210. PubMed ID: 33775329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
    Doishita S; Shimono T; Yoneda T; Yamada E; Tsukamoto T; Takemori D; Kimura D; Tatekawa H; Sakamoto S; Miki Y
    Magn Reson Med Sci; 2018 Jan; 17(1):58-66. PubMed ID: 28867760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
    Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
    Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
    Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis.
    Mu F; Lucas JT; Watts JM; Johnson AJ; Daniel Bourland J; Laxton AW; Chan MD; Tatter SB
    J Clin Neurosci; 2015 Mar; 22(3):561-5. PubMed ID: 25560387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
    Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
    Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
    Sage W; Guilfoyle M; Luney C; Young A; Sinha R; Sgubin D; McAbee JH; Ma R; Jefferies S; Jena R; Harris F; Allinson K; Matys T; Qian W; Santarius T; Price S; Watts C
    J Neurooncol; 2018 Jan; 136(2):273-280. PubMed ID: 29139095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric drug delivery for the treatment of glioblastoma.
    Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.
    Shibahara I; Hanihara M; Watanabe T; Dan M; Sato S; Kuroda H; Inamura A; Inukai M; Hara A; Yasui Y; Kumabe T
    J Neurooncol; 2018 Apr; 137(2):417-427. PubMed ID: 29468445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
    Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
    J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.